omeprazole + dabigatran

Omeprazole + dabigatran is a combination of two pharmaceutical agents used concomitantly, not as a fixed-dose product but as co-administered drugs. Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase in gastric parietal cells. Dabigatran is an oral anticoagulant that acts as a direct thrombin inhibitor, preventing the conversion of fibrinogen to fibrin and thus reducing blood clot formation. This combination may be used in patients requiring anticoagulation with dabigatran who also need acid suppression therapy for gastrointestinal protection or symptom control. Concomitant use of omeprazole and dabigatran can lead to reduced plasma concentrations of dabigatran due to decreased absorption in the higher pH environment created by PPIs like omeprazole. Clinical studies have shown that this interaction can lower both trough and peak levels of dabigatran; however, most evidence suggests these reductions are moderate and generally remain within therapeutic ranges for most patients[1][3][5][6]. The clinical significance remains under investigation, but caution should be exercised due to potential reduction in anticoagulant efficacy[8].

Other names

omeprazole and dabigatranomeprazole plus dabigatran